Company intelligence / Profile preview
Caliway Biopharmaceuticals
New Taipei City, Taiwancaliway.com.tw ↗
- Ownership
- Public · 6919
- Development stage
- Phase 3
01
Overview
CBL-514, the lead candidate, has shown strong efficacy in reducing subcutaneous fat and treating Dercum's disease. In Phase IIb studies for non-invasive fat reduction, over 80% of subjects achieved at least a one-grade improvement with favorable safety. For Dercum's disease, CBL‑514 reduced lipoma size by >50% and improved pain scores significantly. The company has received FDA IND acceptance for further studies and initiated pivotal global trials.
- Therapeutic areas
- EndocrinologyRare DiseasesDermatologyMetabolic Disorders
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Financials
- Market cap
- $3B
- Total revenue
- $1.2M
- Enterprise value
- $2.9B
Beyond the preview
Go deeper on Caliway Biopharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Caliway Biopharmaceuticals.